HR71-118

Introduced

To amend the Federal Food, Drug, and Cosmetic Act to exempt from regulation as devices non-invasive diagnostic devices, and for other purposes.

118th Congress Introduced Jan 9, 2023

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

The bill exempts exempting non-invasive diagnostic devices from regulation as devices Section 201(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. It relies on definition changes and exemptions. The main policy areas are Healthcare and Healthcare Consumers.

Who Benefits and How

Patients and health care consumers affected by the bill could face lower compliance burdens.

Who Bears the Burden and How

Public beneficiaries or protected communities affected by the clause could face increased risk.

Key Provisions

  • Exempts exempting non-invasive diagnostic devices from regulation as devices Section 201(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

The bill exempts exempting non-invasive diagnostic devices from regulation as devices Section 201(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.

Key Policy Areas

Healthcare, Healthcare Consumers

Primary Purpose

The bill exempts exempting non-invasive diagnostic devices from regulation as devices Section 201(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.

Policy Domains

Healthcare Healthcare Consumers

Whole bill

Identified Gains
  • Patients and health care consumers affected by the bill
Model: codex-gpt-5:bulk-repair | Version: bill_summary_v2 | Source: ih
Patients and health care consumers affected by the bill:
Identified Costs
  • Public beneficiaries or protected communities affected by the clause
Model: codex-gpt-5:bulk-repair | Version: bill_summary_v2 | Source: ih
Public beneficiaries or protected communities affected by the clause:

Legislative Progress

Introduced
Introduced Committee Passed
Jan 9, 2023

Mr. Biggs introduced the following bill; which was referred to …

Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Healthcare Healthcare Consumers

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology